Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. (Q38115264)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Mirella Gaboli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Òscar Asensio de la Cruz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

María Isabel Barrio Gómez de Agüero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Guadalupe Pérez Pérez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Manuel Sánchez-Solís de Querol

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

18 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

published in

Pediatric Pulmonology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

490-502

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

Respiratory syncytial virus prevention and therapy: past, present, and future

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Respiratory syncytial virus infection in children with neuromuscular impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Risk factors for severe respiratory syncytial virus lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Consensus in diagnostic definitions for bone or joint infections in children by a Delphi method with European French-speaking experts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Developing a standardized approach to the assessment of pain in children and youth presenting to pediatric rheumatology providers: a Delphi survey and consensus conference process followed by feasibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Defining off-label and unlicensed use of medicines for children: results of a Delphi survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Research priorities for nursing care of infants, children and adolescents: a West Australian Delphi study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

An exploration of the use of simple statistics to measure consensus and stability in Delphi studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

The Asthma Predictive Index: a very useful tool for predicting asthma in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Down syndrome and respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Hospitalizations due to respiratory syncytial virus in children with congenital malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Lower airway inflammation in infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Vaccines for preventing influenza in people with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Prevention of influenza: recommendations for influenza immunization of children, 2007-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Immunisation in the current management of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

CARESS: the Canadian registry of palivizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.22826

21 January 2018

Identifiers

DOI

10.1002/PPUL.22826

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23775884%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference